George M Eid1, Carol McCloskey2, Rebecca Titchner3, Mary Korytkowski4, Debra Gross2, Cynthia Grabowski2, Mark Wilson5. 1. Department of Surgery, Allegheny Health Network, Temple University, Pittsburgh, Pennsylvania; Department of Surgery, Pittsburgh VA Healthcare System, University Drive, Pittsburgh, Pennsylvania. Electronic address: georgemeid@hotmail.com. 2. Division of Minimally Invasive Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 3. Department of Surgery, Pittsburgh VA Healthcare System, University Drive, Pittsburgh, Pennsylvania. 4. Department of Internal Medicine, Endocrinology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 5. Department of Surgery, Pittsburgh VA Healthcare System, University Drive, Pittsburgh, Pennsylvania; Division of Minimally Invasive Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Small retrospective studies have demonstrated reduction in weight and co-morbid hirsutism and diabetes in women with polycystic ovary syndrome (PCOS) treated with Roux-en-Y gastric bypass. The objective of this study was to prospectively determine clinical improvements in obese women with PCOS treated with gastric bypass and identify postoperative biomarker changes. METHODS: Data were collected on obese women with PCOS undergoing Roux-en-Y gastric bypass over 1 year. Testosterone, follicle stimulating hormone, lutenizing hormone, insulin, fasting glucose, and lipid levels were obtained preoperatively at baseline, and 6 and 12 months after surgery. Testosterone was used as the primary hormonal biomarker. A physical examination for body mass index (BMI) and hirsutism, and information on menstrual pattern were collected at baseline and 3, 6, and 12 months after surgery. RESULTS: Data were available for 14 women. Mean BMI decreased from 44.8±5.9 kg/m(2) at baseline to 29.2±5.9 kg/m(2) at 12 months postoperatively. Significant improvements were seen in testosterone, fasting glucose, insulin, cholesterol, and triglyceride at 12 months (P<.05). At baseline, irregular menses were reported in 10 patients; all patients were experiencing regular menses 6 and 12 months after surgery. Hirsutism was present in 11 patients at baseline and only 7 patients at 12 months. Improvements in biomarkers, menstrual cycling, and hirsutism was not correlated with degree of weight change. CONCLUSION: Gastric bypass achieved significant reductions in BMI, testosterone, and markers of glucose and lipid metabolism. These data confirm reports of previous retrospective studies showing weight reduction and health improvement in women with PCOS treated with gastric bypass. Published by Elsevier Inc.
BACKGROUND: Small retrospective studies have demonstrated reduction in weight and co-morbid hirsutism and diabetes in women with polycystic ovary syndrome (PCOS) treated with Roux-en-Y gastric bypass. The objective of this study was to prospectively determine clinical improvements in obesewomen with PCOS treated with gastric bypass and identify postoperative biomarker changes. METHODS: Data were collected on obesewomen with PCOS undergoing Roux-en-Y gastric bypass over 1 year. Testosterone, follicle stimulating hormone, lutenizing hormone, insulin, fasting glucose, and lipid levels were obtained preoperatively at baseline, and 6 and 12 months after surgery. Testosterone was used as the primary hormonal biomarker. A physical examination for body mass index (BMI) and hirsutism, and information on menstrual pattern were collected at baseline and 3, 6, and 12 months after surgery. RESULTS: Data were available for 14 women. Mean BMI decreased from 44.8±5.9 kg/m(2) at baseline to 29.2±5.9 kg/m(2) at 12 months postoperatively. Significant improvements were seen in testosterone, fasting glucose, insulin, cholesterol, and triglyceride at 12 months (P<.05). At baseline, irregular menses were reported in 10 patients; all patients were experiencing regular menses 6 and 12 months after surgery. Hirsutism was present in 11 patients at baseline and only 7 patients at 12 months. Improvements in biomarkers, menstrual cycling, and hirsutism was not correlated with degree of weight change. CONCLUSION: Gastric bypass achieved significant reductions in BMI, testosterone, and markers of glucose and lipid metabolism. These data confirm reports of previous retrospective studies showing weight reduction and health improvement in women with PCOS treated with gastric bypass. Published by Elsevier Inc.
Authors: Hind A Beydoun; May A Beydoun; Sharmin Hossain; Laurel Stadtmauer; Shaker M Eid; Alan B Zonderman Journal: J Womens Health (Larchmt) Date: 2020-02-20 Impact factor: 2.681
Authors: Daniel Skubleny; Noah J Switzer; Richdeep S Gill; Mark Dykstra; Xinzhe Shi; Margaret A Sagle; Christopher de Gara; Daniel W Birch; Shahzeer Karmali Journal: Obes Surg Date: 2016-01 Impact factor: 4.129
Authors: Agostinho S Machado Júnior; Cláudio B L Ribeiro; Fernando Santa-Cruz; Brena F Sena; Jose-Luiz Figueiredo; Álvaro A B Ferraz; Josemberg M Campos Journal: Obes Surg Date: 2019-08 Impact factor: 4.129